A Phase 2 interventional study of Afimkibart in Atopic Dermatitis, sponsored by Hoffmann-La Roche. Active, not recruiting at 31 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Dermatitis, Atopic with a site in Brazil — 2 open to participants now, 12 under way, 6 of them phase 3. Dermatitis, Atopic · Brazil.
Among the 38 studies in Dermatitis, Atopic with a site in Brazil, this one is the 24th largest by planned enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 10 of the 11 other live ones, and was the 35th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 38 studies in Dermatitis, Atopic with a site in Brazil are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Brazil, United States, Argentina and 10 more countries
Ages 6 mo–18 yrs
Brainfarma Industria Química e Farmacêutica S/A · Sites in Brazil
Ages 3–65
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 20 · Phase 4 5
First in 2009; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 310 across the 35 interventional studies, 266 across the 3 observational. Of the 24 that completed or were terminated, 7 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 38 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 6 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
3 of the studies in Dermatitis, Atopic with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT07230860Janssen Research & Development, LLCA Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis | 2026-11-19 |
| NCT07918560Brainfarma Industria Química e Farmacêutica S/ACosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis | 2027-03-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Dermatitis, Atopic with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Parent Clinical Trial-Specific Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Afimkibart as subcutaneous (SC) injection.
Drug: Afimkibart
Participants will receive Afimkibart as SC injection.
Drug: Afimkibart
Afimkibart SC injection will be administered as per the schedule defined in the protocol.
Also known as: RO7790121, PF-06480605, RVT-3101
Percentage of Participants with Adverse Events
Time frame: From Baseline up to 6 years
Change From Baseline (in Parent Study) in Eczema Area and Severity Index (EASI) Score at Each Visit
Time frame: Baseline, Up to 6 years
Percent Change From Baseline (in Parent Study) in EASI Score at Each Visit
Time frame: Baseline, Up to 6 years
Percentage of Participants With EASI-50 at Each Visit
Time frame: Up to 6 years
Percentage of Participants with EASI-75 at Each Visit
Time frame: Up to 6 years
Percentage of Participants with EASI-90 at Each Visit
Time frame: Up to 6 years
Percentage of Participants who Achieve Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) of Clear (0) or Almost clear (1) at Each Visit
Time frame: From Baseline up to 6 years
Change from Baseline (in the parent study) in Participant-Oriented Eczema Measure (POEM) at Each Visit
Time frame: Baseline, Up to 6 years
Change from Baseline (in the parent study) in Dermatology Life Quality Index (DLQI) at Each Visit
Time frame: Baseline, Up to 6 years
Serum Concentration of Afimkibart at Specified Timepoints
Time frame: Pre-dose on Day 1, Weeks 2, 10, 18, 26, 34, 42, 50 74, 98, 122, 146, 170, 194, 218, 242, 266, 290 and 14 weeks after last dose
Percentage of Participants with Anti-Drug Antibodies (ADAs) to Afimkibart
Time frame: From Baseline up to 6 years
Percentage of Participants with Neutralizing Antibody (NAb) to Afimkibart
Time frame: From Baseline up to 6 years
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Jan 2026 (actual). Primary completion is estimated for Mar 2033, 85 months after the start.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 85 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afimkibart